Skip to main content
Premium Trial:

Request an Annual Quote

Quidel Issues $172.5M of Senior Convertible Notes

NEW YORK(GenomeWeb) – Quidel said today in a regulatory document that it is issuing $172.5 million of its senior convertible notes. 

The issuance of the 3.25 percent senior notes due in 2020 is part of a deal between Quidel and the Bank of New York Mellon Trust. The notes will be senior unsecured obligations of Quidel, it said in a document filed with the US Securities and Exchange Commission. 

Quidel announced the public offering of $150 million in convertible senior notes last week. Net proceeds will go toward working capital and other general corporate purposes, which may include acquisitions of products, technologies, or businesses, and share repurchases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.